The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer
NCT06477055 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60
Last updated 2026-04-13
Summary
This study was a multicenter, real-world observational study aimed at characterizing the genomic landscape of recurrence in patients with EGFR-sensitizing mutation-positive early-stage (clinical stage IB-IIIA) non-small cell lung cancer who received adjuvant osimertinib after surgery.
Conditions
Sponsors & Collaborators
-
Hunan Province Tumor Hospital
lead OTHER
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-12-02
- Primary Completion
- 2026-03-31
- Completion
- 2026-04-30
Countries
- China
Study Locations
More Related Trials
-
A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Disease Recurrence After Complete Resection
NCT05514314 ·Status: UNKNOWN ·Phase: PHASE2
-
Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer
NCT06752408 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma
NCT05165355 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations
NCT03434418 ·Status: COMPLETED ·Phase: PHASE2
-
Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma
NCT06383728 ·Status: RECRUITING ·Phase: PHASE2
-
Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC
NCT05215951 ·Status: TERMINATED ·Phase: PHASE2
-
Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer
NCT03460275 ·Status: UNKNOWN ·Phase: PHASE2
-
Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer
NCT05513664 ·Status: UNKNOWN
-
A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC
NCT07058519 ·Status: RECRUITING ·Phase: PHASE2
-
Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR Inhibitors
NCT04338243 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
NCT04322890 ·Status: RECRUITING ·Phase: PHASE2
-
Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC
NCT05536505 ·Status: RECRUITING ·Phase: PHASE2
-
JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations
NCT06391944 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC
NCT04324164 ·Status: RECRUITING
-
Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC
NCT05011487 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
NCT04351555 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)
NCT05686434 ·Status: RECRUITING ·Phase: PHASE2
-
EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study
NCT06486142 ·Status: RECRUITING ·Phase: PHASE3
-
Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC
NCT06376084 ·Status: ACTIVE_NOT_RECRUITING
-
A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations
NCT06735391 ·Status: RECRUITING ·Phase: PHASE3
-
Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer
NCT04425681 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.
NCT05785208 ·Status: RECRUITING ·Phase: PHASE4
-
A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06670196 ·Status: RECRUITING ·Phase: PHASE3
-
Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer
NCT04974879 ·Status: UNKNOWN ·Phase: PHASE2
-
Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).
NCT05219162 ·Status: COMPLETED ·Phase: PHASE4